Cole is a senior scientist in the Platform Development group focused on enabling high-throughput antibody discovery. Prior to joining Cartography, he worked in the lab of Jim Wells where he developed novel single-domain antibody libraries for use as immunotherapies and antivirals. He holds a Ph.D. in Chemistry and Chemical Biology from UCSF. In his free time, Cole enjoys rock climbing, racing marathons, and reading comics
Recent Posts
- Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
- Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
- Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
- Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
- Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
Recent Comments
No comments to show.